Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NasoShield

Vaccine (Adenoviral vector) · Immune activation · developed by Altimmune

Phase 1 Most advanced trial (none active)

ALT Developer

1 Registered trials

What is NasoShield?

NasoShield is an adenovirus-vectored anthrax vaccine.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Adenoviral vector)
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: Altimmune, Inc. (ALT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03352466	Phase 1	Healthy Volunteers	Completed	ALT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Altimmune

AdCOVID Phase 1 FP-02.2 Vaccine Phase 1 HepTcell Phase 2 NasoVAX Phase 2 Pemvidutide Phase 3

Sources

ClinicalTrials.gov NCT03352466

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALT page.

Follow ALT, the company behind NasoShield

See ALT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z